Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Scleroderma treatment could leap forward with FT011 drug candidate

By Brian Buntz | February 8, 2023

Certa TherapeuticsThe story of the scleroderma drug candidate FT011 is one of “tenacity and persistence,” said Darren Kelly, CEO and managing director of Certa Therapeutics, which is developing the drug.

The drug was discovered around 2006 by Kelly’s laboratory at the University of Melbourne and Spencer Williams of the Bio21 Institute.

“It was really [Williams] being the chemist and me being the biologist working together on a problem and developing FT011,” Kelly said.

The drug was the lead asset of a company known as Fibrotech, where Kelly was CEO.  Shire acquired the company in 2014. At that time, the drug had finished a Phase 1A study and was in a Phase 1B diabetic nephropathy trial.

In 2019, Takeda completed the acquisition of Shire, shelving several programs.

“We worked with Shire to take back FT011 and all the technology that was around that, and then set up Certa Therapeutics in 2018,” said Kelly

FT011 offers promise in scleroderma

Darren Kelly

Darren Kelly

Scleroderma is a rare autoimmune connective tissue and rheumatic disease with a generally poor prognosis. A 2019 study found that patients with the condition have a worse quality of life than those with lupus or rheumatoid arthritis.

Currently available treatments focus on managing symptoms.

Conversely, the focus of the FT011 program is to stop fibrosis, “which is a big problem with patients with scleroderma because they get scar tissue in a range of organs — their skin, potentially in their lungs, kidneys and heart,” Kelly said. “It’s quite a debilitating condition.”

In a recent Phase 2 study, FT011 supported significant clinical improvements in more than 60% of scleroderma patients.

Certa is optimistic that the drug could help improve the quality of life for scleroderma patients, who are often diagnosed between the ages of 30 and 50. The condition affects women more often than men.

“If you can do something and improve their quality of life and these patients can go back to work and feel a lot better, then it’s a huge benefit to society,” Kelly said.

Looking for a partner

Certa is currently designing a worldwide Phase 3 trial for FT011 in scleroderma with a goal of launching the study later in 2023. The study will likely run for 12 months and involve a couple hundred patients in the U.S., Europe, Australia and Asia.

“The goal for the company is to partner with a bigger pharma that is more experienced at doing a Phase 3 and marketing a new drug,” Kelly said.

The company is currently in active discussions with “quite a few large pharmas at the moment,” Kelly said. In particular, Certa is looking for a strategic partner that “fits in this category of immunology, scleroderma or rheumatoid arthritis,” he added.

“We’re engaging in those discussions over time and working toward a partnership as we speak. So it’s an ongoing process.”


Filed Under: clinical trials, Drug Discovery, Rheumatology
Tagged With: FT011, scleroderma
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Rosnilimab phase 2b trial shows promise in treating RA
rosnilimab
PD-1 agonists show promise in treating rheumatoid arthritis by restoring immune balance 
Zai Lab
Zai Lab’s unified approach to tackling cancer, autoimmune, and neurological diseases
Johnson & Johnson
How a J&J exec found her calling in autoantibody drug development
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE